Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Indications of Generics to Be Brought in Line with Those of Original Products
July 3, 2006
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
July 3, 2006
- 7 Complaints Received Regarding Supply of Generics: EAD
July 3, 2006
- Shionogi to Develop In-House Products Overseas Through PIIb: Dr Teshirogi
July 3, 2006
- Original Makers Suspected of Obstructing Generic Houses' Business: JFTC
July 3, 2006
- Takeda Ties-Up with Cephalon
June 26, 2006
- JPMA
June 26, 2006
- Mediceo Paltac to Acquire
June 26, 2006
- NEW PRODUCTS
June 26, 2006
- Lilly Initiates PIII Study
June 26, 2006
- Amended PAL Will Create New Business
June 26, 2006
- HMW Fucoidan Inhibits
June 26, 2006
- Healthcare Reform-related Bill Passes the Diet
June 26, 2006
- 8th Meeting of JSCPS
June 26, 2006
- New Drug Data Protection
June 26, 2006
- R&D NEWS IN BRIEF
June 26, 2006
- PFSB Considers Drastic Changes
June 26, 2006
- Otsuka's Abilify Receives Prix Galien
June 26, 2006
- FPMAJ's Drug Price Study Committee
June 26, 2006
- 12% of Pharmacists Report
June 26, 2006
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…